Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02807636
Registration number
NCT02807636
Ethics application status
Date submitted
17/06/2016
Date registered
21/06/2016
Date last updated
29/04/2024
Titles & IDs
Public title
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Query!
Scientific title
A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as Monotherapy and in Combination With Platinum-Based Chemotherapy in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Query!
Secondary ID [1]
0
0
2016-000250-35
Query!
Secondary ID [2]
0
0
WO30070
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
IMvigor130
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Urothelial Carcinoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Non melanoma skin cancer
Query!
Cancer
0
0
0
0
Query!
Kidney
Query!
Cancer
0
0
0
0
Query!
Bladder - transitional cell cancer
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Atezolizumab
Treatment: Drugs - Carboplatin
Treatment: Drugs - Gemcitabine
Other interventions - Placebo
Treatment: Drugs - Cisplatin
Experimental: Atezolizumab+Gemcitabine+Carboplatin/Cisplatin - Participants will receive blinded atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).
Placebo Comparator: Placebo+Gemcitabine+Carboplatin/Cisplatin - Participants will receive blinded placebo matched to atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).
Experimental: Atezolizumab Monotherapy - Eligible participants will receive open-label atezolizumab as monotherapy.
Treatment: Drugs: Atezolizumab
Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
Treatment: Drugs: Carboplatin
Carboplatin will be administered at doses to achieve area under the concentration-time curve (AUC) of 4.5 milligram per milliliter into minute (mg/mL*min) by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
Treatment: Drugs: Gemcitabine
Gemcitabine will be administered at a dose of 1000 milligrams per square meter (mg/m^2) by IV infusion on Day 1 and Day 8 of each 21-day cycle, until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
Other interventions: Placebo
Placebo matched to atezolizumab will be administered by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
Treatment: Drugs: Cisplatin
Cisplatin will be administered at a dose of 70 mg/m^2 by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Investigator Assessed Progression-Free Survival (PFS) in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm
Query!
Assessment method [1]
0
0
PFS is defined as the time from randomization to the first documented disease progression as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever occurs first.
Query!
Timepoint [1]
0
0
Baseline up to first documented disease progression or death, whichever occurs first (up to approximately 35 months)
Query!
Primary outcome [2]
0
0
Overall Survival (OS) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Query!
Assessment method [2]
0
0
OS is defined as the time from randomization to death due to any cause.
Query!
Timepoint [2]
0
0
Baseline until death due to any cause (up to approximately 73 months)
Query!
Primary outcome [3]
0
0
Overall Survival (OS) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Query!
Assessment method [3]
0
0
OS is defined as the time from randomization to death due to any cause.
Query!
Timepoint [3]
0
0
Baseline until death due to any cause (up to approximately 73 months)
Query!
Secondary outcome [1]
0
0
Objective Response Rate (ORR) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Query!
Assessment method [1]
0
0
Objective response rate (ORR) is defined as the proportion of participants with a confirmed objective response, either complete response (CR) or partial response (PR), observed on two assessments >= 28 days apart per RECIST v1.1, based on investigator assessment. The analysis population for ORR will be all randomized participants with measurable disease at baseline.
Query!
Timepoint [1]
0
0
Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)
Query!
Secondary outcome [2]
0
0
Objective Response Rate (ORR) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Query!
Assessment method [2]
0
0
Objective response rate (ORR) is defined as the proportion of participants with a confirmed objective response, either complete response (CR) or partial response (PR), observed on two assessments >= 28 days apart per RECIST v1.1, based on investigator assessment. The analysis population for ORR will be all randomized participants with measurable disease at baseline.
Query!
Timepoint [2]
0
0
Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)
Query!
Secondary outcome [3]
0
0
Duration of Response (DOR) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Query!
Assessment method [3]
0
0
Duration of response (DOR) is defined for participants with an objective response as the time from the first documented objective response to documented disease progression per RECIST v1.1, based on investigator assessment, or death due to any cause, whichever occurs first.
Query!
Timepoint [3]
0
0
From first documented objective response (CR or PR) to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)
Query!
Secondary outcome [4]
0
0
Duration of Response (DOR) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Query!
Assessment method [4]
0
0
Duration of response (DOR) is defined for participants with an objective response as the time from the first documented objective response to documented disease progression per RECIST v1.1, based on investigator assessment, or death due to any cause, whichever occurs first.
Query!
Timepoint [4]
0
0
From first documented objective response (CR or PR) to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)
Query!
Secondary outcome [5]
0
0
IRF-PFS
Query!
Assessment method [5]
0
0
Independent review facility PFS (IRF-PFS) is defined as the time from randomization to the first documented disease progression as determined by blinded independent central review with use of RECIST v1.1, or death due to any cause, whichever occurs first.
Query!
Timepoint [5]
0
0
Randomization to first documented disease progression or death from any cause (up to 35 months)
Query!
Secondary outcome [6]
0
0
OS Event Free Rate Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Query!
Assessment method [6]
0
0
Overall Survival (OS) Event Free Rate at 1 Year.
Query!
Timepoint [6]
0
0
Year 1
Query!
Secondary outcome [7]
0
0
OS Event Free Rate in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Query!
Assessment method [7]
0
0
Overall Survival (OS) Event Free Rate at 1 Year.
Query!
Timepoint [7]
0
0
Year 1
Query!
Secondary outcome [8]
0
0
PFS Event Free Rate
Query!
Assessment method [8]
0
0
Progression Free Survival (PFS) Event Free Rate at Year 1
Query!
Timepoint [8]
0
0
Year 1
Query!
Secondary outcome [9]
0
0
Time to Deterioration in Global Health Status as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm
Query!
Assessment method [9]
0
0
Time to deterioration in global health status as measured by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm.
Query!
Timepoint [9]
0
0
Up to approximately 73 months
Query!
Secondary outcome [10]
0
0
Time to Deterioration in Global Health Status as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab Monotherapy Arm
Query!
Assessment method [10]
0
0
Time to deterioration in global health status as measured by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 in the Placebo+Chemo Arm versus Atezolizumab Monotherapy Arm.
Query!
Timepoint [10]
0
0
Up to approximately 73 months
Query!
Secondary outcome [11]
0
0
Time to Deterioration in Physical Function as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm
Query!
Assessment method [11]
0
0
Median time to deterioration in physical function as measured by the QLQ-C30 in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm.
Query!
Timepoint [11]
0
0
Up to approximately 73 months
Query!
Secondary outcome [12]
0
0
Time to Deterioration in Physical Function as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab Monotherapy Arm
Query!
Assessment method [12]
0
0
Median time to deterioration in physical function as measured by the QLQ-C30 in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm versus Atezolizumab Monotherapy Arm.
Query!
Timepoint [12]
0
0
Up to approximately 73 months
Query!
Secondary outcome [13]
0
0
Maximum Atezolizumab Serum Concentration
Query!
Assessment method [13]
0
0
Maximum atezolizumab serum concentration.
Query!
Timepoint [13]
0
0
Cycle 1 Day 1
Query!
Secondary outcome [14]
0
0
Minimum Atezolizumab Serum Concentration
Query!
Assessment method [14]
0
0
Minimum atezolizumab serum concentration.
Query!
Timepoint [14]
0
0
Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 8 Day 1, Cycle 16 Day 1, Cycle 24 Day 1, Cycle 32 Day 1, Day 120 post dose of last blinded atezolizumab treatment, and study drug early discontinuation
Query!
Secondary outcome [15]
0
0
Percentage of Participants With Anti-Therapeutic (Anti-Atezolizumab) Antibodies (ATAs)
Query!
Assessment method [15]
0
0
Percentage of participants with Anti-Therapeutic (Anti-Atezolizumab) Antibodies (ATAs).
Query!
Timepoint [15]
0
0
Up to approximately 35 months
Query!
Secondary outcome [16]
0
0
Investigator-Assessed Progression-Free Survival (INV-PFS) in Participants Treated With Atezolizumab Monotherapy Arm Compared With Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Query!
Assessment method [16]
0
0
PFS is defined as the time from randomization to the first documented disease progression as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever occurs first.
Query!
Timepoint [16]
0
0
Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (assessed at baseline, every 9 weeks for 54 weeks and every 12 weeks thereafter up to 35 months)
Query!
Secondary outcome [17]
0
0
Percentage of Participants With Adverse Events (AEs) Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Query!
Assessment method [17]
0
0
Query!
Timepoint [17]
0
0
Baseline up to 90 months
Query!
Eligibility
Key inclusion criteria
Inclusion Criteria
- Considered to be eligible to receive platinum-based chemotherapy, in the
investigator's judgment
- Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to
(</=) 2
- Histologically documented, locally advanced (T4b, any N; or any T, N2-3) or metastatic
urothelial carcinoma (mUC) (M1, Stage IV) (also termed transitional cell carcinoma
[TCC] or urothelial cell carcinoma [UCC] of the urinary tract; including renal pelvis,
ureters, urinary bladder, and urethra)
- Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin
blocks (blocks preferred) or at least 15 unstained slides, with an associated
pathology report, for central testing and determined to be evaluable for tumor PD-L1
expression prior to study enrollment; participants who have fewer than 15 unstained
slides available at baseline (but no less than [<] 10) may be eligible following
discussion with the Medical Monitor
- No prior chemotherapy for inoperable locally advanced or mUC
- For participants who received prior adjuvant/neoadjuvant chemotherapy or
chemo-radiation for urothelial carcinoma, a treatment-free interval more than (>) 12
months between the last treatment administration and the date of recurrence is
required in order to be considered treatment naive in the metastatic setting
- Prior local intravesical chemotherapy or immunotherapy is allowed if completed at
least 4 weeks prior to the initiation of study treatment
- Measurable disease, as defined by RECIST v1.1
- Adequate hematologic and end-organ function
- For women of childbearing potential: agreement to remain abstinent (refrain from
heterosexual intercourse) or use contraceptive methods that result in a failure rate
of <1% per year during the treatment period and for at least 6 months after the last
dose of carboplatin, cisplatin, or gemcitabine or for 5 months after the last dose of
atezolizumab
- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use
contraceptive measures and agreement to refrain from donating sperm
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3
weeks prior to initiation of study treatment
- Treatment with any other investigational agent or participation in another clinical
study with therapeutic intent within 28 days prior to enrolment
- Active or untreated CNS metastases as determined by computed tomography (CT) or
magnetic resonance imaging evaluation during screening and prior radiographic
assessments
- Participants with treated asymptomatic central nervous system (CNS) metastases are
eligible, provided they meet all of the following criteria: * Evaluable or measurable
disease outside the CNS * No metastases to midbrain, pons, medulla, or within 10 mm of
the optic apparatus (optic nerves and chiasm) * No history of intracranial or spinal
cord hemorrhage * No ongoing requirement for corticosteroid as therapy for CNS
disease; anti-convulsants at a stable dose are allowed * No evidence of significant
vasogenic edema * No stereotactic radiation, whole-brain radiation or neurosurgical
resection within 4 weeks prior to Cycle 1, Day 1 * Radiographic demonstration of
interim stability (i.e., no progression) between the completion of CNS-directed
therapy and the screening radiographic study * Screening CNS radiographic study >/=4
weeks since completion of radiotherapy or surgical resection and >/=2 weeks since
discontinuation of corticosteroids
- Prior treatment with CD137 agonists, anti-CTLA-4, anti-programmed death-1 (PD-1), or
anti-PD-L1 therapeutic antibody or pathway-targeting agents
- Treatment with systemic corticosteroids or other systemic immunosuppressive
medications (including but not limited to prednisone, dexamethasone, cyclophosphamide,
azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [TNF] agents)
within 2 weeks prior to Cycle 1, Day 1 or anticipated requirement for systemic
immunosuppressive medications during the study
- Leptomeningeal disease
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent
drainage procedures (once monthly or more frequently)
- Uncontrolled tumour-related pain or hypercalcemia
- Significant cardiovascular disease including known left ventricular ejection fraction
(LVEF) <40%
- Severe infections within 4 weeks before randomization or therapeutic oral or IV
antibiotics within 2 weeks before randomization
- Major surgical procedure within 4 weeks prior to randomization or anticipation of need
for a major surgical procedure during the course of the study other than for diagnosis
- Malignancies other than urothelial carcinoma within 5 years prior to Cycle 1, Day 1
- Life expectancy of <12 weeks
- Pregnant or lactating, or intending to become pregnant during the study
- Serum albumin <25 gram per liter (g/L)
- History of severe allergic, anaphylactic, or other hypersensitivity reactions to
chimeric or humanized antibodies or fusion proteins
- Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster
ovary cells or any component of the atezolizumab formulation
- History of autoimmune disease
- Participants with prior allogeneic stem cell or solid organ transplantation
- History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced
pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic
organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan
- Positive test for human immunodeficiency virus (HIV)
- Active hepatitis B or hepatitis C
- Active tuberculosis
- Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
30/06/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
12/02/2024
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1213
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
Macquarie University Hospital - Macquarie Park
Query!
Recruitment hospital [2]
0
0
Royal Brisbane and Women's Hospital - Herston
Query!
Recruitment hospital [3]
0
0
Lyell McEwin Hospital - Adelaide
Query!
Recruitment hospital [4]
0
0
Ashford Cancer Center Research - Kurralta Park
Query!
Recruitment hospital [5]
0
0
Box Hill Hospital - Box Hill
Query!
Recruitment hospital [6]
0
0
Cabrini Medical Centre; Oncology - Malvern
Query!
Recruitment hospital [7]
0
0
Sunshine Hospital; Oncology Research - St Albans
Query!
Recruitment postcode(s) [1]
0
0
2109 - Macquarie Park
Query!
Recruitment postcode(s) [2]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [3]
0
0
5112 - Adelaide
Query!
Recruitment postcode(s) [4]
0
0
5037 - Kurralta Park
Query!
Recruitment postcode(s) [5]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [6]
0
0
3144 - Malvern
Query!
Recruitment postcode(s) [7]
0
0
- St Albans
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arkansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Delaware
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kentucky
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Louisiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Minnesota
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Nevada
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New York
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
North Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
South Carolina
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Tennessee
Query!
Country [16]
0
0
Belgium
Query!
State/province [16]
0
0
Charleroi
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Gent
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Leuven
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Liege
Query!
Country [20]
0
0
Bosnia and Herzegovina
Query!
State/province [20]
0
0
Banja Luka
Query!
Country [21]
0
0
Bosnia and Herzegovina
Query!
State/province [21]
0
0
Sarajevo
Query!
Country [22]
0
0
Brazil
Query!
State/province [22]
0
0
MG
Query!
Country [23]
0
0
Brazil
Query!
State/province [23]
0
0
RJ
Query!
Country [24]
0
0
Brazil
Query!
State/province [24]
0
0
RS
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
SC
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
SP
Query!
Country [27]
0
0
Canada
Query!
State/province [27]
0
0
Alberta
Query!
Country [28]
0
0
Canada
Query!
State/province [28]
0
0
British Columbia
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
New Brunswick
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
Ontario
Query!
Country [31]
0
0
Chile
Query!
State/province [31]
0
0
Recoleta
Query!
Country [32]
0
0
Chile
Query!
State/province [32]
0
0
Santiago
Query!
Country [33]
0
0
Chile
Query!
State/province [33]
0
0
Vitacura
Query!
Country [34]
0
0
China
Query!
State/province [34]
0
0
Beijing City
Query!
Country [35]
0
0
China
Query!
State/province [35]
0
0
Beijing
Query!
Country [36]
0
0
China
Query!
State/province [36]
0
0
Chongqing
Query!
Country [37]
0
0
China
Query!
State/province [37]
0
0
Guangzhou
Query!
Country [38]
0
0
China
Query!
State/province [38]
0
0
Nanjing City
Query!
Country [39]
0
0
China
Query!
State/province [39]
0
0
Shanghai City
Query!
Country [40]
0
0
China
Query!
State/province [40]
0
0
Shanghai
Query!
Country [41]
0
0
China
Query!
State/province [41]
0
0
Tianjin
Query!
Country [42]
0
0
Czechia
Query!
State/province [42]
0
0
Brno
Query!
Country [43]
0
0
Czechia
Query!
State/province [43]
0
0
Olomouc
Query!
Country [44]
0
0
Czechia
Query!
State/province [44]
0
0
Praha 2
Query!
Country [45]
0
0
Czechia
Query!
State/province [45]
0
0
Praha 5
Query!
Country [46]
0
0
Estonia
Query!
State/province [46]
0
0
Tallinn
Query!
Country [47]
0
0
Finland
Query!
State/province [47]
0
0
Oulu
Query!
Country [48]
0
0
Finland
Query!
State/province [48]
0
0
Turku
Query!
Country [49]
0
0
Georgia
Query!
State/province [49]
0
0
Tbilisi
Query!
Country [50]
0
0
Greece
Query!
State/province [50]
0
0
Athens
Query!
Country [51]
0
0
Greece
Query!
State/province [51]
0
0
Patras
Query!
Country [52]
0
0
Hong Kong
Query!
State/province [52]
0
0
Hong Kong
Query!
Country [53]
0
0
Hong Kong
Query!
State/province [53]
0
0
N.t.
Query!
Country [54]
0
0
Israel
Query!
State/province [54]
0
0
Haifa
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Campania
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Emilia-Romagna
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Lazio
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Liguria
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Lombardia
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Piemonte
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Puglia
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Toscana
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Umbria
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Veneto
Query!
Country [65]
0
0
Japan
Query!
State/province [65]
0
0
Aichi
Query!
Country [66]
0
0
Japan
Query!
State/province [66]
0
0
Aomori
Query!
Country [67]
0
0
Japan
Query!
State/province [67]
0
0
Ehime
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Gunma
Query!
Country [69]
0
0
Japan
Query!
State/province [69]
0
0
Hokkaido
Query!
Country [70]
0
0
Japan
Query!
State/province [70]
0
0
Ibaraki
Query!
Country [71]
0
0
Japan
Query!
State/province [71]
0
0
Ishikawa
Query!
Country [72]
0
0
Japan
Query!
State/province [72]
0
0
Kumamoto
Query!
Country [73]
0
0
Japan
Query!
State/province [73]
0
0
Niigata
Query!
Country [74]
0
0
Japan
Query!
State/province [74]
0
0
Osaka
Query!
Country [75]
0
0
Japan
Query!
State/province [75]
0
0
Tokyo
Query!
Country [76]
0
0
Korea, Republic of
Query!
State/province [76]
0
0
Daegu
Query!
Country [77]
0
0
Korea, Republic of
Query!
State/province [77]
0
0
Incheon
Query!
Country [78]
0
0
Korea, Republic of
Query!
State/province [78]
0
0
Seoul
Query!
Country [79]
0
0
Malaysia
Query!
State/province [79]
0
0
FED. Territory OF Kuala Lumpur
Query!
Country [80]
0
0
Mexico
Query!
State/province [80]
0
0
Jalisco
Query!
Country [81]
0
0
Mexico
Query!
State/province [81]
0
0
Mexico CITY (federal District)
Query!
Country [82]
0
0
Mexico
Query!
State/province [82]
0
0
Nuevo LEON
Query!
Country [83]
0
0
Mexico
Query!
State/province [83]
0
0
Queretaro
Query!
Country [84]
0
0
Netherlands
Query!
State/province [84]
0
0
Den-Haag
Query!
Country [85]
0
0
Netherlands
Query!
State/province [85]
0
0
Groningen
Query!
Country [86]
0
0
Netherlands
Query!
State/province [86]
0
0
Sittard-Geleen
Query!
Country [87]
0
0
Netherlands
Query!
State/province [87]
0
0
Zwolle
Query!
Country [88]
0
0
Poland
Query!
State/province [88]
0
0
Bialystok
Query!
Country [89]
0
0
Poland
Query!
State/province [89]
0
0
Konin
Query!
Country [90]
0
0
Poland
Query!
State/province [90]
0
0
Kraków
Query!
Country [91]
0
0
Poland
Query!
State/province [91]
0
0
Lodz
Query!
Country [92]
0
0
Poland
Query!
State/province [92]
0
0
Poznan
Query!
Country [93]
0
0
Poland
Query!
State/province [93]
0
0
Tomaszów Mazowiecki
Query!
Country [94]
0
0
Poland
Query!
State/province [94]
0
0
Warszawa
Query!
Country [95]
0
0
Poland
Query!
State/province [95]
0
0
Wroclaw
Query!
Country [96]
0
0
Portugal
Query!
State/province [96]
0
0
Lisboa
Query!
Country [97]
0
0
Portugal
Query!
State/province [97]
0
0
Porto
Query!
Country [98]
0
0
Romania
Query!
State/province [98]
0
0
Baia Mare
Query!
Country [99]
0
0
Romania
Query!
State/province [99]
0
0
Bucharest
Query!
Country [100]
0
0
Romania
Query!
State/province [100]
0
0
Craiova
Query!
Country [101]
0
0
Russian Federation
Query!
State/province [101]
0
0
Altaj
Query!
Country [102]
0
0
Russian Federation
Query!
State/province [102]
0
0
Baskortostan
Query!
Country [103]
0
0
Russian Federation
Query!
State/province [103]
0
0
Krasnodar
Query!
Country [104]
0
0
Russian Federation
Query!
State/province [104]
0
0
Moskovskaja Oblast
Query!
Country [105]
0
0
Russian Federation
Query!
State/province [105]
0
0
Niznij Novgorod
Query!
Country [106]
0
0
Russian Federation
Query!
State/province [106]
0
0
Sankt Petersburg
Query!
Country [107]
0
0
Russian Federation
Query!
State/province [107]
0
0
Sverdlovsk
Query!
Country [108]
0
0
Russian Federation
Query!
State/province [108]
0
0
Ivanovo
Query!
Country [109]
0
0
Serbia
Query!
State/province [109]
0
0
Belgrade
Query!
Country [110]
0
0
Serbia
Query!
State/province [110]
0
0
Nis
Query!
Country [111]
0
0
Serbia
Query!
State/province [111]
0
0
Sremska Kamenica
Query!
Country [112]
0
0
Singapore
Query!
State/province [112]
0
0
Singapore
Query!
Country [113]
0
0
Slovenia
Query!
State/province [113]
0
0
Ljubljana
Query!
Country [114]
0
0
South Africa
Query!
State/province [114]
0
0
George
Query!
Country [115]
0
0
South Africa
Query!
State/province [115]
0
0
Port Elizabeth
Query!
Country [116]
0
0
South Africa
Query!
State/province [116]
0
0
Pretoria
Query!
Country [117]
0
0
South Africa
Query!
State/province [117]
0
0
Sandton
Query!
Country [118]
0
0
Spain
Query!
State/province [118]
0
0
Alicante
Query!
Country [119]
0
0
Spain
Query!
State/province [119]
0
0
Barcelona
Query!
Country [120]
0
0
Spain
Query!
State/province [120]
0
0
Cantabria
Query!
Country [121]
0
0
Spain
Query!
State/province [121]
0
0
Castellon
Query!
Country [122]
0
0
Spain
Query!
State/province [122]
0
0
Cordoba
Query!
Country [123]
0
0
Spain
Query!
State/province [123]
0
0
Islas Baleares
Query!
Country [124]
0
0
Spain
Query!
State/province [124]
0
0
Navarra
Query!
Country [125]
0
0
Spain
Query!
State/province [125]
0
0
Pontevedra
Query!
Country [126]
0
0
Spain
Query!
State/province [126]
0
0
Vizcaya
Query!
Country [127]
0
0
Spain
Query!
State/province [127]
0
0
Albacete
Query!
Country [128]
0
0
Spain
Query!
State/province [128]
0
0
Burgos
Query!
Country [129]
0
0
Spain
Query!
State/province [129]
0
0
Caceres
Query!
Country [130]
0
0
Spain
Query!
State/province [130]
0
0
Granada
Query!
Country [131]
0
0
Spain
Query!
State/province [131]
0
0
Huelva
Query!
Country [132]
0
0
Spain
Query!
State/province [132]
0
0
Jaen
Query!
Country [133]
0
0
Spain
Query!
State/province [133]
0
0
Leon
Query!
Country [134]
0
0
Spain
Query!
State/province [134]
0
0
Lugo
Query!
Country [135]
0
0
Spain
Query!
State/province [135]
0
0
Madrid
Query!
Country [136]
0
0
Spain
Query!
State/province [136]
0
0
Sevilla
Query!
Country [137]
0
0
Spain
Query!
State/province [137]
0
0
Toledo
Query!
Country [138]
0
0
Spain
Query!
State/province [138]
0
0
Valencia
Query!
Country [139]
0
0
Spain
Query!
State/province [139]
0
0
Zaragoza
Query!
Country [140]
0
0
Taiwan
Query!
State/province [140]
0
0
Kaohisung
Query!
Country [141]
0
0
Taiwan
Query!
State/province [141]
0
0
Taichung
Query!
Country [142]
0
0
Taiwan
Query!
State/province [142]
0
0
Tainan
Query!
Country [143]
0
0
Taiwan
Query!
State/province [143]
0
0
Taipei
Query!
Country [144]
0
0
Taiwan
Query!
State/province [144]
0
0
Taoyuan
Query!
Country [145]
0
0
Thailand
Query!
State/province [145]
0
0
Bangkok
Query!
Country [146]
0
0
Thailand
Query!
State/province [146]
0
0
ChiangMai
Query!
Country [147]
0
0
Turkey
Query!
State/province [147]
0
0
Adana
Query!
Country [148]
0
0
Turkey
Query!
State/province [148]
0
0
Ankara
Query!
Country [149]
0
0
Turkey
Query!
State/province [149]
0
0
Edirne
Query!
Country [150]
0
0
Turkey
Query!
State/province [150]
0
0
Istanbul
Query!
Country [151]
0
0
Turkey
Query!
State/province [151]
0
0
Kadiköy
Query!
Country [152]
0
0
Turkey
Query!
State/province [152]
0
0
Kar??yaka
Query!
Country [153]
0
0
Turkey
Query!
State/province [153]
0
0
Samsun
Query!
Country [154]
0
0
Turkey
Query!
State/province [154]
0
0
Sihhiye/Ankara
Query!
Country [155]
0
0
Ukraine
Query!
State/province [155]
0
0
Kharkiv Governorate
Query!
Country [156]
0
0
Ukraine
Query!
State/province [156]
0
0
Dnipropetrovsk
Query!
Country [157]
0
0
Ukraine
Query!
State/province [157]
0
0
Zaporizhzhia
Query!
Country [158]
0
0
United Kingdom
Query!
State/province [158]
0
0
Glasgow
Query!
Country [159]
0
0
United Kingdom
Query!
State/province [159]
0
0
London
Query!
Country [160]
0
0
United Kingdom
Query!
State/province [160]
0
0
Manchester
Query!
Country [161]
0
0
United Kingdom
Query!
State/province [161]
0
0
York
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
A Phase III, randomised study of atezolizumab alone and in combination with chemotherapy
versus chemotherapy alone in participants with untreated advanced urothelial cancer.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02807636
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02807636
Download to PDF